siRNA nanotherapeutics: a Trojan horse approach against HIV

Vijay Mishra; Prashant Kesharwani; Narendra K Jain

doi:10.1016/j.drudis.2014.09.019

siRNA nanotherapeutics: a Trojan horse approach against HIV

Drug Discov Today. 2014 Dec;19(12):1913-20. doi: 10.1016/j.drudis.2014.09.019. Epub 2014 Oct 2.

Authors

Vijay Mishra¹, Prashant Kesharwani¹, Narendra K Jain²

Affiliations

¹ Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr H.S. Gour Central University, Sagar, MP, India.
² Pharmaceutics Research Laboratory, Department of Pharmaceutical Sciences, Dr H.S. Gour Central University, Sagar, MP, India. Electronic address: jnarendr@yahoo.co.in.

PMID: 25281591
DOI: 10.1016/j.drudis.2014.09.019

Abstract

The concept of RNA interference (RNAi) is gaining popularity for the better management of various diseases, including HIV. Currently, the successful biomedical utilization of siRNA therapeutics is hampered, both in vivo and in vitro, mainly by the inherent inability of naked siRNA to cross the cell membrane. RNAi can potentially improve the weakness of current highly active antiretroviral therapy (HAART) by diminishing the chances of the appearance of antiHIV-resistant strains. Here, we discuss the nanocarrier-mediated delivery of siRNA delivery as well as highlighted the scope of siRNA-mediated gene-silencing technology for improved HIV treatment.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Drug Carriers / administration & dosage*
Drug Carriers / therapeutic use
Drug Carriers / toxicity
Genome, Viral
HIV Infections / therapy*
HIV-1 / genetics
HIV-1 / physiology
Humans
Nanoparticles / administration & dosage*
Nanoparticles / therapeutic use
Nanoparticles / toxicity
RNA Interference
RNA, Small Interfering / administration & dosage*
RNA, Small Interfering / therapeutic use
RNA, Small Interfering / toxicity

Substances

Drug Carriers
RNA, Small Interfering